

enhanced nasal absorption of said apomorphine compound to produce a therapeutic result in said subject within about 30 minutes or less.

22. The nasally administered pharmaceutical composition of Claim 21, wherein administration of said apomorphine compound in said formulation for enhanced nasal delivery yields enhanced nasal absorption of said apomorphine compound to produce a therapeutic result in said subject within about 15 minutes or less.

23. A nasally administered pharmaceutical formulation for treating sexual dysfunction in a mammalian subject comprising a therapeutically effective amount of an apomorphine compound in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said apomorphine compound resulting in a time to maximal plasma concentration of said apomorphine compound in said subject of about 20 minutes or less.

24. The nasally administered pharmaceutical composition of Claim 23, wherein administration of said apomorphine compound in said formulation for enhanced nasal delivery yields enhanced nasal absorption resulting in a time to maximal plasma concentration of said apomorphine compound in said subject of about 15 minutes or less.

29. The nasally administered pharmaceutical composition of Claim 21, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

30. The nasally administered pharmaceutical composition of Claim 23, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

31. The nasally administered pharmaceutical composition of Claim 21, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

32. The nasally administered pharmaceutical composition of Claim 23, wherein said apomorphine compound is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

39. A nasally administered pharmaceutical formulation for treating difficulty in achieving or inability of achieving orgasm in a female mammalian subject comprising a therapeutically effective amount of an apomorphine compound in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said apomorphine compound resulting in a time to maximal plasma concentration of said dopamine receptor agonist in said subject of about 20 minutes or less.

REMARKS

Status of the Claims

Claims 21-32 and 39 will be pending after entry of this amendment. Claims 33-38 and 40 were withdrawn from consideration as noted below. Claims 21-24, 29-32 and 39 have been amended. Support for the amendments can be found throughout the specification. For example, support can be found at page 3, l. 13 to 17. Claim amendments are for purposes of improved clarity or consistency of claim language unless otherwise noted. No claim amendment should be construed as an acquiescence in any ground of rejection. No new matter has been added by this amendment.

Claim 39 is objected to because a claim term is redundant. Claims 21-28 and 39 are rejected under 35 U.S.C. § 102(b) as being anticipated by Cincinelli et al (1996) in view of *American Hospital Formulary Service* (1988) and Heaton et al. (1995).

Applicants use the paragraph numbering in the Office Action (Paper No. 8) in responding to the examiner's remarks.